Stockreport

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics, Inc.  (CGTX) 
PDF Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in [Read more]